PPARγ maintains ERBB2-positive breast cancer stem cells

Oncogene

Volumn 32, Issue 49, 2013, Pages 5512-5521

  Wang, X ^a   Sun, Y ^a   Wong, J ^a   Conklin, D S ^a  

^a STATE UNIVERSITY OF NEW YORK   (United States)

Author keywords

HER2 neu positive; PPARg; stem cells

Indexed keywords

2 CHLORO 5 NITRO N (4 PYRIDYL)BENZAMIDE; 2 CHLORO 5 NITROBENZANILIDE; ACETYLCYSTEINE; ALDEHYDE DEHYDROGENASE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HISTONE H3; HISTONE H4; KRUPPEL LIKE FACTOR 4; NUCLEAR RECEPTOR NR1D1; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; REACTIVE OXYGEN METABOLITE; ROSIGLITAZONE;

ARTICLE; BREAST CANCER; CARCINOGENESIS; CONTROLLED STUDY; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; PRIORITY JOURNAL; STEM CELL; TUMOR GENE; TUMOR SEEDING;

ACETYLCYSTEINE; ALDEHYDE DEHYDROGENASE; ANILIDES; ANIMALS; BENZAMIDES; BREAST NEOPLASMS; CELL LINE, TUMOR; FEMALE; HUMANS; MCF-7 CELLS; MEDIATOR COMPLEX SUBUNIT 1; MICE; MICE, INBRED NOD; MICE, SCID; NEOPLASM TRANSPLANTATION; NEOPLASTIC STEM CELLS; NUCLEAR RECEPTOR SUBFAMILY 1, GROUP D, MEMBER 1; PPAR GAMMA; PYRIDINES; REACTIVE OXYGEN SPECIES; RECEPTOR, ERBB-2;

EID: 84890563878     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2013.217     Document Type: Article

References (61)

1. Menard S, Fortis S, Castiglioni F, Agresti R, Balsari A. HER2 as a prognostic factor in breast cancer. Oncology 2001; 61(Suppl 2): 67-72.
2. Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002; 20: 719-726.
3. Lapidot T, Sirard C, Vormoor J, Murdoch B, Hoang T, Caceres-Cortes J et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 1994; 367: 645-648.
4. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 2003; 100: 3983-3988.
5. Smalley M, Ashworth A. Stem cells and breast cancer: a field in transit. Nat Rev Cancer 2003; 3: 832-844.
6. Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006; 444: 756-760.
7. Li X, Lewis MT, Huang J, Gutierrez C, Osborne CK, Wu MF et al. Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Cancer Inst 2008; 100: 672-679.
8. Eyler CE, Rich JN. Survival of the fittest: cancer stem cells in therapeutic resistance and angiogenesis. J Clin Oncol 2008; 26: 2839-2845.
9. Diehn M, Clarke MF. Cancer stem cells and radiotherapy: new insights into tumor radioresistance. J Natl Cancer Inst 2006; 98: 1755-1757.
10. Bedard PL, Cardoso F, Piccart-Gebhart MJ. Stemming resistance to HER-2 targeted therapy. J Mammary Gland Biol Neoplasia 2009; 14: 55-66.
11. Oliveras-Ferraros C, Vazquez-Martin A, Martin-Castillo B, Cufi S, Del Barco S, Lopez- Bonet E et al. Dynamic emergence of the mesenchymal CD44(pos)CD24(neg/low) phenotype in HER2-gene amplified breast cancer cells with de novo resistance to trastuzumab (Herceptin). Biochem Biophys Res Commun 2010; 397: 27-33.
12. Fumagalli D, Michiels S, Sotiriou C. CD44 CD24-/low phenotype and resistance to trastuzumab in HER2-positive breast cancer cell lines. Pharmacogenomics 2011; 12: 12-13.
13. Baumann J, Karch C, Kourtidis A, Conklin DS. The electronics of HER2/neu positive breast cancer cells. Breast Cancer Recent Adv Biol Imaging Ther 2012: 17-36.
14. Kourtidis A, Jain R, Carkner RD, Eifert C, Brosnan MJ, Conklin DS. An RNA interference screen identifies metabolic regulators NR1D1 and PBP as novel survival factors for breast cancer cells with the ERBB2 signature. Cancer Res 2010; 70: 1783-1792.
15. Chin K, DeVries S, Fridlyand J, Spellman PT, Roydasgupta R, Kuo WL et al. Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. Cancer Cell 2006; 10: 529-541.
16. Kauraniemi P, Kallioniemi A. Activation of multiple cancer-Associated genes at the ERBB2 amplicon in breast cancer. Endocr Relat Cancer 2006; 13: 39-49.
17. Dressman MA, Baras A, Malinowski R, Alvis LB, Kwon I, Walz TM et al. Gene expression profiling detects gene amplification and differentiates tumor types in breast cancer. Cancer Res 2003; 63: 2194-2199.
18. Zhu Y, Qi C, Jain S, Le Beau MM, Espinosa 3rd R, Atkins GB et al. Amplification and overexpression of peroxisome proliferator-Activated receptor binding protein (PBP/PPARBP) gene in breast cancer. Proc Natl Acad Sci USA 1999; 96: 10848-10853.
19. Bertucci F, Borie N, Ginestier C, Groulet A, Charafe-Jauffret E, Adelaide J et al. Identification and validation of an ERBB2 gene expression signature in breast cancers. Oncogene 2004; 23: 2564-2575.
20. Kourtidis A, Srinivasaiah R, Carkner RD, Brosnan MJ, Conklin DS. Peroxisome proliferator-Activated receptor-gamma protects ERBB2-positive breast cancer cells from palmitate toxicity. Breast Cancer Res 2009; 11: R16.
21. Evans RM, Barish GD, Wang YX. PPARs and the complex journey to obesity. Nat Med 2004; 10: 355-361.
22. Lehrke M, Lazar MA. The many faces of PPARgamma. Cell 2005; 123: 993-999.
23. Michalik L, Desvergne B, Wahli W. Peroxisome-proliferator-Activated receptors and cancers: complex stories. Nat Rev Cancer 2004; 4: 61-70.
24. Glazer RI, Yuan H, Xie Z, Yin Y. PPARgamma and PPARdelta as modulators of neoplasia and cell fate. PPAR Res 2008; 2008: 247379.
25. Pignatelli M, Cortes-Canteli M, Lai C, Santos A, Perez-Castillo A. The peroxisome proliferator-Activated receptor gamma is an inhibitor of ErbBs activity in human breast cancer cells. J Cell Sci 2001; 114: 4117-4126.
26. Kim KY, Kim SS, Cheon HG. Differential anti-proliferative actions of peroxisome proliferator-Activated receptor-gamma agonists in MCF-7 breast cancer cells. Biochem Pharmacol 2006; 72: 530-540.
27. Mueller E, Sarraf P, Tontonoz P, Evans RM, Martin KJ, Zhang M et al. Terminal differentiation of human breast cancer through PPAR gamma. Mol Cell 1998; 1: 465-470.
28. Yin F, Wakino S, Liu Z, Kim S, Hsueh WA, Collins AR et al. Troglitazone inhibits growth of MCF-7 breast carcinoma cells by targeting G1 cell cycle regulators. Biochem Biophys Res Comm 2001; 286: 916-922.
29. Elstner E, Williamson EA, Zang C, Fritz J, Heber D, Fenner M et al. Novel therapeutic approach: ligands for PPARgamma and retinoid receptors induce apoptosis in bcl-2-positive human breast cancer cells. Breast Cancer Res Treat 2002; 74: 155-165.
30. Yang Z, Bagheri-Yarmand R, Balasenthil S, Hortobagyi G, Sahin AA, Barnes CJ et al. HER2 regulation of peroxisome proliferator-Activated receptor gamma (PPARgamma) expression and sensitivity of breast cancer cells to PPARgamma ligand therapy. Clin Cancer Res 2003; 9: 3198-3203.
31. He X, Esteva FJ, Ensor J, Hortobagyi GN, Lee MH, Yeung SC. Metformin and thiazolidinediones are associated with improved breast cancer-specific survival of diabetic women with HER2 breast cancer. Ann Oncol 2012; 23: 1771-1780.
32. Chearwae W, Bright JJ. PPARgamma agonists inhibit growth and expansion of CD133 brain tumour stem cells. Br J Cancer 2008; 99: 2044-2053.
33. Tsao T, Kornblau S, Safe S, Watt JC, Ruvolo V, Chen W et al. Role of peroxisome proliferator-Activated receptor-gamma and its coactivator DRIP205 in cellular responses to CDDO (RTA-401) in acute myelogenous leukemia. Cancer Res 2010; 70: 4949-4960.
34. Wu L, Yan C, Czader M, Foreman O, Blum JS, Kapur R et al. Inhibition of PPARgamma in myeloid-lineage cells induces systemic inflammation, immunosuppression, and tumorigenesis. Blood 2012; 119: 115-126.
35. Reka AK, Kurapati H, Narala VR, Bommer G, Chen J, Standiford TJ et al. Peroxisome proliferator-Activated receptor-gamma activation inhibits tumor metastasis by antagonizing Smad3-mediated epithelial-mesenchymal transition. Mol Cancer Ther 2010; 9: 3221-3232.
36. Kuniyasu H. The roles of dietary PPARgamma ligands for metastasis in colorectal cancer. PPAR Res 2008; 2008: 529720.
37. Tian L, Zhou J, Casimiro MC, Liang B, Ojeifo JO, Wang M et al. Activating peroxisome proliferator-Activated receptor gamma mutant promotes tumor growth in vivo by enhancing angiogenesis. Cancer Res 2009; 69: 9236-9244.
38. Korkaya H, Paulson A, Iovino F, Wicha MS. HER2 regulates the mammary stem/ progenitor cell population driving tumorigenesis and invasion. Oncogene 2008; 27: 6120-6130.
39. Ginestier C, Hur MH, Charafe-Jauffret E, Monville F, Dutcher J, Brown M et al. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 2007; 1: 555-567.
40. Menendez JA, Vellon L, Mehmi I, Oza BP, Ropero S, Colomer R et al. Inhibition of fatty acid synthase (FAS) suppresses HER2/neu (erbB-2) oncogene overexpression in cancer cells. Proc Natl Acad Sci USA 2004; 101: 10715-10720.
41. Sebastiani V, Botti C, Di Tondo U, Visca P, Pizzuti L, Santeusanio G et al. Tissue microarray analysis of FAS, Bcl-2, Bcl-x, ER, PgR, Hsp60, p53 and Her2-neu in breast carcinoma. Anticancer Res 2006; 26: 2983-2987.
42. Silva SD, Agostini M, Nishimoto IN, Coletta RD, Alves FA, Lopes MA et al. Expression of fatty acid synthase, ErbB2 and Ki-67 in head and neck squamous cell carcinoma: a clinicopathological study. Oral Oncol 2004; 40: 688-696.
43. Kumar-Sinha C, Ignatoski KW, Lippman ME, Ethier SP, Chinnaiyan AM. Transcriptome analysis of HER2 reveals a molecular connection to fatty acid synthesis. Cancer Res 2003; 63: 132-139.
44. Lee JJ, Drakaki A, Iliopoulos D, Struhl K. MiR-27b targets PPARgamma to inhibit growth, tumor progression and the inflammatory response in neuroblastoma cells. Oncogene 2012; 31: 3818-3825.
45. Wellen KE, Hatzivassiliou G, Sachdeva UM, Bui TV, Cross JR, Thompson CB. ATPcitrate lyase links cellular metabolism to histone acetylation. Science 2009; 324: 1076-1080.
46. Swinnen JV, Brusselmans K, Verhoeven G. Increased lipogenesis in cancer cells: new players, novel targets. Curr Opin Clin Nutr Metab Care 2006; 9: 358-365.
47. Robbins GT, Nie D. PPAR gamma, bioactive lipids, and cancer progression. Front Biosci 2012; 17: 1816-1834.
48. Mehta RG, Williamson E, Patel MK, Koeffler HP. A ligand of peroxisome proliferator- activated receptor gamma, retinoids, and prevention of preneoplastic mammary lesions. J Natl Cancer Inst 2000; 92: 418-423.
49. Liu H, Zang C, Fenner MH, Possinger K, Elstner E. PPARgamma ligands and ATRA inhibit the invasion of human breast cancer cells in vitro. Breast Cancer Res Treat 2003; 79: 63-74.
50. Burton JD, Goldenberg DM, Blumenthal RD. Potential of peroxisome proliferatoractivated receptor gamma antagonist compounds as therapeutic agents for a wide range of cancer types. PPAR Res 2008; 2008: 494161.
51. Rageul J, Mottier S, Jarry A, Shah Y, Theoleyre S, Masson D et al. KLF4-dependent, PPARgamma-induced expression of GPA33 in colon cancer cell lines. Int J Cancer 2009; 125: 2802-2809.
52. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006; 126: 663-676.
53. Yuan H, Kopelovich L, Yin Y, Lu J, Glazer RI. Drug-targeted inhibition of peroxisome proliferator-Activated receptor-gamma enhances the chemopreventive effect of anti-estrogen therapy. Oncotarget 2012; 3: 345-356.
54. Sutton-McDowall ML, Feil D, Robker RL, Thompson JG, Dunning KR. Utilization of endogenous fatty acid stores for energy production in bovine preimplantation embryos. Theriogenology 2012; 77: 1632-1641.
55. Ferguson EM, Leese HJ. A potential role for triglyceride as an energy source during bovine oocyte maturation and early embryo development. Mol Reprod Dev 2006; 73: 1195-1201.
56. Zu XY, Zhang QH, Liu JH, Cao RX, Zhong J, Yi GH et al. ATP citrate lyase inhibitors as novel cancer therapeutic agents. Recent Pat Anticancer Drug Discov 2012; 7: 154-167.
57. Debnath J, Muthuswamy SK, Brugge JS. Morphogenesis and oncogenesis of MCF- 10A mammary epithelial acini grown in three-dimensional basement membrane cultures. Methods 2003; 30: 256-268.
58. Hauser S, Adelmant G, Sarraf P, Wright HM, Mueller E, Spiegelman BM. Degradation of the peroxisome proliferator-Activated receptor gamma is linked to ligand-dependent activation. J Biol Chem 2000; 275: 18527-18533.
59. Patrawala L, Calhoun T, Schneider-Broussard R, Zhou J, Claypool K, Tang DG. Side population is enriched in tumorigenic, stem-like cancer cells, whereas ABCG2 and ABCG2- cancer cells are similarly tumorigenic. Cancer Res 2005; 65: 6207-6219.
60. Christgen M, Ballmaier M, Lehmann U, Kreipe H. Detection of putative cancer stem cells of the side population phenotype in human tumor cell cultures. Methods Mol Biol 2012; 878: 201-215.
61. Wang X, Lu H, Urvalek AM, Li T, Yu L, Lamar J et al. KLF8 promotes human breast cancer cell invasion and metastasis by transcriptional activation of MMP9. Oncogene 2011; 30: 1901-1911.